TR Therapeutics

Quick facts

Phase 3 pipeline

• TR987 0.1% gel + Standard of Care · Dermatology
  TR987 0.1% gel works by targeting the existing mechanism of standard of care to enhance its effects.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• TR Therapeutics portfolio CI brief
• TR Therapeutics pipeline updates RSS